Thetis Pharmaceuticals Announces Patent Issuance in Australia for First-in-Class RvE1 Drug Candidate that Targets the LTB4-BLT1 Pathway
Essex, CT – (October 12, 2023) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class, oral small molecule Resolvin E1-based drug to treat chronic inflammatory diseases and cancer, announced that it has been granted patent AU 2018374863 providing composition of matter protection for TP-317 in Australia, where Thetis plans to conduct a Phase 1a trial of oral TP-317 in healthy subjects in early 2024.
“TP-317 is a highly differentiated approach to regulating immune homeostasis with broad therapeutic potential in cancer and autoimmune diseases,” said Gary Mathias, co-founder and CEO of Thetis. “With long-term patents issued in the U.S., Europe, Japan, China, Korea and Australia, TP-317 has the intellectual property foundation to support clinical development in major markets.”
About Thetis Pharmaceuticals
Thetis is a pharmaceutical company advancing into clinical studies focused on developing innovative treatments for inflammatory bowel disease and cancer. Thetis’ lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug candidate that engages the LTB4-BLT1 pathway to mobilize the body’s ability to resolve disease and restore immune homeostasis. Thetis is supported by private investors, the National Institutes of Health, and prominent philanthropies, including the Helmsley Charitable Trust, Crohn's & Colitis Foundation, and the Kenneth Rainin Foundation.
Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.
Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com.